Business Description
Yabao Pharmaceutical Group Co Ltd
NAICS : 325412
No.43 Fumin Road, Ruicheng, Shanxi Province, Yuncheng, CHN, 044602
Compare
Compare
Traded in other countries / regions
600351.China
Description
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.9 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | 2.33 | |||||
Interest Coverage | 11.7 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 4.15 | |||||
Beneish M-Score | -2.74 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.6 | |||||
3-Year EBITDA Growth Rate | -9.6 | |||||
3-Year EPS without NRI Growth Rate | -11.6 | |||||
3-Year FCF Growth Rate | -1.3 | |||||
3-Year Book Growth Rate | 1 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59.7 | |||||
9-Day RSI | 50.69 | |||||
14-Day RSI | 47.53 | |||||
6-1 Month Momentum % | -8.95 | |||||
12-1 Month Momentum % | 0.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.9 | |||||
Quick Ratio | 1.38 | |||||
Cash Ratio | 0.53 | |||||
Days Inventory | 167.41 | |||||
Days Sales Outstanding | 66.96 | |||||
Days Payable | 61.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.28 | |||||
Dividend Payout Ratio | 0.2 | |||||
3-Year Dividend Growth Rate | -20.6 | |||||
Forward Dividend Yield % | 1.28 | |||||
5-Year Yield-on-Cost % | 0.89 | |||||
3-Year Average Share Buyback Ratio | 0.7 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 60.84 | |||||
Operating Margin % | 9.12 | |||||
Net Margin % | 7.27 | |||||
ROE % | 6.68 | |||||
ROA % | 4.72 | |||||
ROIC % | 6.49 | |||||
ROC (Joel Greenblatt) % | 10.43 | |||||
ROCE % | 7.98 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 25.02 | |||||
PE Ratio without NRI | 25.06 | |||||
Shiller PE Ratio | 27.34 | |||||
Price-to-Owner-Earnings | 43.34 | |||||
PEG Ratio | 8.08 | |||||
PS Ratio | 1.83 | |||||
PB Ratio | 1.61 | |||||
Price-to-Tangible-Book | 1.84 | |||||
Price-to-Free-Cash-Flow | 17.01 | |||||
Price-to-Operating-Cash-Flow | 13.6 | |||||
EV-to-EBIT | 20.04 | |||||
EV-to-EBITDA | 20.04 | |||||
EV-to-Revenue | 1.84 | |||||
EV-to-FCF | 16.77 | |||||
Price-to-Projected-FCF | 1.01 | |||||
Price-to-Median-PS-Value | 0.74 | |||||
Price-to-Graham-Number | 1.43 | |||||
Price-to-Net-Current-Asset-Value | 6.64 | |||||
Earnings Yield (Greenblatt) % | 4.98 | |||||
Forward Rate of Return (Yacktman) % | 7.42 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 2,665.047 | ||
EPS (TTM) (¥) | 0.249 | ||
Beta | 1.56 | ||
Volatility % | 70.9 | ||
14-Day RSI | 47.53 | ||
14-Day ATR (¥) | 0.151172 | ||
20-Day SMA (¥) | 6.23 | ||
12-1 Month Momentum % | 0.48 | ||
52-Week Range (¥) | 5.48 - 11.9 | ||
Shares Outstanding (Mil) | 770 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Yabao Pharmaceutical Group Co Ltd Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |